Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67


Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.

Hilton JF, Clemons M, Pond G, Zhao H, Mazzarello S, Vandermeer L, Addison CL.

J Bone Oncol. 2017 Nov 8;10:6-13. doi: 10.1016/j.jbo.2017.11.001. eCollection 2018 Mar.


MicroRNA-30b controls endothelial cell capillary morphogenesis through regulation of transforming growth factor beta 2.

Howe GA, Kazda K, Addison CL.

PLoS One. 2017 Oct 4;12(10):e0185619. doi: 10.1371/journal.pone.0185619. eCollection 2017.


A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.

Laurie SA, Hao D, Leighl NB, Goffin J, Khomani A, Gupta A, Addison CL, Bane A, Seely J, Filion ML, Pond GR, Levine MN.

Lung Cancer. 2017 Feb;104:65-69. doi: 10.1016/j.lungcan.2016.12.004. Epub 2016 Dec 15.


A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer.

Addison CL, Simos D, Wang Z, Pond G, Smith S, Robertson S, Mazzarello S, Singh G, Vandermeer L, Fernandes R, Iyengar A, Verma S, Clemons M.

J Bone Oncol. 2016 Jul 1;5(4):173-179. doi: 10.1016/j.jbo.2016.06.003. eCollection 2016 Nov.


Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.

Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, Addison CL, Kuchuk I, Zhu X, Gelmon K, Arnaout A.

Cancer Metastasis Rev. 2016 Sep;35(3):427-37. doi: 10.1007/s10555-016-9631-3. Review.


Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.

Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.

PLoS One. 2016 Mar 10;11(3):e0150567. doi: 10.1371/journal.pone.0150567. eCollection 2016.


Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.

Addison CL, Pond GR, Cochrane B, Zhao H, Chia SK, Levine MN, Clemons M.

J Bone Oncol. 2015 Jun 12;4(2):47-53. doi: 10.1016/j.jbo.2015.04.001. eCollection 2015 Jun.


Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo.

Jia D, Tan Y, Liu H, Ooi S, Li L, Wright K, Bennett S, Addison CL, Wang L.

Oncotarget. 2016 Jan 5;7(1):771-85. doi: 10.18632/oncotarget.5819.


Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.

Addison CL, Ding K, Seymour L, Zhao H, Laurie SA, Shepherd FA, Goss GD, Bradbury PA.

Lung Cancer. 2015 Nov;90(2):288-95. doi: 10.1016/j.lungcan.2015.09.004. Epub 2015 Sep 16.


VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, Howe GA, Bourgeois-Daigneault MC, Conrad DP, Daneshmand M, Breitbach CJ, Kirn DH, Raptis L, Sad S, Atkins H, Huh MS, Diallo JS, Lichty BD, Ilkow CS, Le Boeuf F, Addison CL, McCart JA, Bell JC.

Cancer Cell. 2015 Aug 10;28(2):210-24. doi: 10.1016/j.ccell.2015.06.009. Epub 2015 Jul 23.


Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.

Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L, Addison CL, Shepherd FA, Goss GD, Dimitroulakos J, Bradbury PA.

Clin Lung Cancer. 2015 Nov;16(6):e189-201. doi: 10.1016/j.cllc.2015.05.002. Epub 2015 May 13.


Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC.

Nat Med. 2015 May;21(5):530-6. doi: 10.1038/nm.3848. Epub 2015 Apr 20.


Evaluating the feasibility of performing window of opportunity trials in breast cancer.

Arnaout A, Robertson S, Kuchuk I, Simos D, Pond GR, Addison CL, Namazi M, Clemons M.

Int J Surg Oncol. 2015;2015:785793. doi: 10.1155/2015/785793. Epub 2015 Jan 20.


Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.

Addison CL, Pond GR, Zhao H, Mazzarello S, Vandermeer L, Goldstein R, Amir E, Clemons M.

Springerplus. 2014 Oct 1;3:577. doi: 10.1186/2193-1801-3-577. eCollection 2014.


Essential role for the SLK protein kinase in embryogenesis and placental tissue development.

Al-Zahrani KN, Sekhon P, Tessier DR, Yockell-Lelievre J, Pryce BR, Baron KD, Howe GA, Sriram RK, Daniel K, Mckay M, Lo V, Quizi J, Addison CL, Gruslin A, Sabourin LA.

Dev Dyn. 2014 May;243(5):640-51.


A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M.

Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.


Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers.

Kuchuk I, Beaumont JL, Clemons M, Amir E, Addison CL, Cella D.

J Bone Oncol. 2013 Aug 8;2(4):154-7. doi: 10.1016/j.jbo.2013.07.004. eCollection 2013 Dec.


Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre.

Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M.

J Bone Oncol. 2013 Oct 3;2(4):137-44. doi: 10.1016/j.jbo.2013.09.001. eCollection 2013 Dec.


The ZOOM trial: more boon than doom?

Hutton B, Addison CL, Clemons M.

Lancet Oncol. 2013 Sep;14(10):e387-8. doi: 10.1016/S1470-2045(13)70297-3. No abstract available.


A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.

Hutton B, Addison CL, Campbell K, Fergusson D, Mazarello S, Clemons M.

J Bone Oncol. 2013 May 15;2(3):123-31. doi: 10.1016/j.jbo.2013.05.001. eCollection 2013 Sep. Review.


Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey.

Hutton B, Morretto P, Emmenegger U, Mazzarello S, Kuchuk I, Addison CL, Crawley F, Canil C, Malone S, Berry S, Fergusson D, Clemons M.

J Bone Oncol. 2013 Jun 21;2(3):105-9. doi: 10.1016/j.jbo.2013.05.002. eCollection 2013 Sep.


miR-105 inhibits prostate tumour growth by suppressing CDK6 levels.

Honeywell DR, Cabrita MA, Zhao H, Dimitroulakos J, Addison CL.

PLoS One. 2013 Aug 7;8(8):e70515. doi: 10.1371/journal.pone.0070515. eCollection 2013.


Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists.

Kuchuk I, Mazzarello S, Butterfield K, Appleton A, Addison CL, Clemons M.

J Bone Oncol. 2013 Jan 1;2(1):38-46. doi: 10.1016/j.jbo.2012.12.001. eCollection 2013 Feb. Review.


Incidence and consequences of bone metastases in lung cancer patients.

Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P.

J Bone Oncol. 2013 Jan 17;2(1):22-9. doi: 10.1016/j.jbo.2012.12.004. eCollection 2013 Feb.


Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases.

Simos D, Addison CL, Kuchuk I, Hutton B, Mazzarello S, Clemons M.

J Clin Med. 2013 Aug 19;2(3):67-88. doi: 10.3390/jcm2030067. Review.


A national portfolio of bone oncology trials-The Canadian experience in 2012.

Kuchuk I, Simos D, Addison CL, Clemons M.

J Bone Oncol. 2012 Oct 17;1(3):95-100. doi: 10.1016/j.jbo.2012.09.001. eCollection 2012 Dec. Review.


Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?

Russell K, Clemons M, Costa L, Addison CL.

J Bone Oncol. 2012 May 24;1(1):12-7. doi: 10.1016/j.jbo.2012.04.003. eCollection 2012 Jun. Review.


β1 integrin: an emerging player in the modulation of tumorigenesis and response to therapy.

Howe GA, Addison CL.

Cell Adh Migr. 2012 Mar-Apr;6(2):71-7. doi: 10.4161/cam.20077. Epub 2012 Mar 1.


Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated?

Clemons M, Russell K, Costa L, Addison CL.

Breast Cancer Res Treat. 2012 Jul;134(2):453-7. doi: 10.1007/s10549-012-2077-6. Epub 2012 May 5. Review.


Distinct profile of vascular progenitor attachment to extracellular matrix proteins in cancer patients.

Labonté L, Li Y, Addison CL, Brand M, Javidnia H, Corsten M, Burns K, Allan DS.

Clin Invest Med. 2012 Apr 1;35(2):E86-95.


RhoB controls endothelial cell morphogenesis in part via negative regulation of RhoA.

Howe GA, Addison CL.

Vasc Cell. 2012 Feb 8;4:1. doi: 10.1186/2045-824X-4-1.


Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease.

Vickers MM, Bar J, Gorn-Hondermann I, Yarom N, Daneshmand M, Hanson JE, Addison CL, Asmis TR, Jonker DJ, Maroun J, Lorimer IA, Goss GD, Dimitroulakos J.

Clin Exp Metastasis. 2012 Feb;29(2):123-32. doi: 10.1007/s10585-011-9435-3. Epub 2011 Nov 26.


β1 integrin is required for anchorage-independent growth and invasion of tumor cells in a context dependent manner.

Schooley AM, Andrews NM, Zhao H, Addison CL.

Cancer Lett. 2012 Mar 28;316(2):157-67. doi: 10.1016/j.canlet.2011.10.032. Epub 2011 Oct 30.


Focal adhesion kinase inhibitors are potent anti-angiogenic agents.

Cabrita MA, Jones LM, Quizi JL, Sabourin LA, McKay BC, Addison CL.

Mol Oncol. 2011 Dec;5(6):517-26. doi: 10.1016/j.molonc.2011.10.004. Epub 2011 Oct 20.


Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.

Addison CL, Ding K, Zhao H, Le Maître A, Goss GD, Seymour L, Tsao MS, Shepherd FA, Bradbury PA.

J Clin Oncol. 2010 Dec 20;28(36):5247-56. doi: 10.1200/JCO.2010.31.0805. Epub 2010 Nov 15.


Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors.

Zhao TT, Trinh D, Addison CL, Dimitroulakos J.

PLoS One. 2010 Sep 3;5(9):e12563. doi: 10.1371/journal.pone.0012563.


Precipitation and selective extraction of human serum endogenous peptides with analysis by quadrupole time-of-flight mass spectrometry reveals posttranslational modifications and low-abundance peptides.

Williams D, Ackloo S, Zhu P, Bowden P, Evans KR, Addison CL, Lock C, Marshall JG.

Anal Bioanal Chem. 2010 Feb;396(3):1223-47. doi: 10.1007/s00216-009-3345-0. Epub 2009 Dec 22.


Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells.

Delaney CE, Hopkins SP, Addison CL.

Cancer Lett. 2007 Jul 18;252(2):195-207. Epub 2007 Feb 2.


Comparison of a reference region model with direct measurement of an AIF in the analysis of DCE-MRI data.

Yankeelov TE, Cron GO, Addison CL, Wallace JC, Wilkins RC, Pappas BA, Santyr GE, Gore JC.

Magn Reson Med. 2007 Feb;57(2):353-61.


Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress.

Blais JD, Addison CL, Edge R, Falls T, Zhao H, Wary K, Koumenis C, Harding HP, Ron D, Holcik M, Bell JC.

Mol Cell Biol. 2006 Dec;26(24):9517-32. Epub 2006 Oct 9.


The inhibitory effects of endostatin on endothelial cells are modulated by extracellular matrix.

Delaney CE, Weagant BT, Addison CL.

Exp Cell Res. 2006 Aug 1;312(13):2476-89. Epub 2006 Apr 22.


The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent.

Addison CL, Nör JE, Zhao H, Linn SA, Polverini PJ, Delaney CE.

BMC Cell Biol. 2005 Oct 31;6:38.


CXC chemokines mechanism of action in regulating tumor angiogenesis.

Moore BB, Arenberg DA, Addison CL, Keane MP, Polverini PJ, Strieter RM.

Angiogenesis. 1998;2(2):123-34.


Use of Immunodeficient Mice for the Evaluation of CXC Chemokines in the Regulation of Tumor-associated Angiogenesis.

Strieter RM, Addison CL, Ehlert JE, Keane MP, Belperio JA, Burdick MD, Arenberg DA.

ILAR J. 1999 Sep;40(4):175-182.


Engineering and characterization of functional human microvessels in immunodeficient mice.

Nör JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, Addison CL, Mooney DJ, Polverini PJ.

Lab Invest. 2001 Apr;81(4):453-63.


The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity.

Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM.

J Immunol. 2000 Nov 1;165(9):5269-77.


CXC chemokines in angiogenesis.

Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM.

J Leukoc Biol. 2000 Jul;68(1):1-8. Review.


The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis.

Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM.

Hum Gene Ther. 2000 Jan 20;11(2):247-61.


Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors.

Parks RJ, Bramson JL, Wan Y, Addison CL, Graham FL.

J Virol. 1999 Oct;73(10):8027-34.

Supplemental Content

Loading ...
Support Center